These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 9748119)

  • 1. Prevention of intestinal toxic effects and intensification of irinotecan's therapeutic efficacy against murine colon cancer liver metastases by oral administration of the lipopeptide JBT 3002.
    Shinohara H; Killion JJ; Kuniyasu H; Kumar R; Fidler IJ
    Clin Cancer Res; 1998 Sep; 4(9):2053-63. PubMed ID: 9748119
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral administration of the immunomodulator JBT-3002 induces endogenous interleukin 15 in intestinal macrophages for protection against irinotecan-mediated destruction of intestinal epithelium.
    Shinohara H; Killion JJ; Bucana CD; Yano S; Fidler IJ
    Clin Cancer Res; 1999 Aug; 5(8):2148-56. PubMed ID: 10473099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intensified regression of colon cancer liver metastases in mice treated with irinotecan and the immunomodulator JBT 3002.
    Shinohara H; Bucana CD; Killion JJ; Fidler IJ
    J Immunother; 2000; 23(3):321-31. PubMed ID: 10838661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapy of human pancreatic carcinoma implants by irinotecan and the oral immunomodulator JBT 3002 is associated with enhanced expression of inducible nitric oxide synthase in tumor-infiltrating macrophages.
    Bruns CJ; Shinohara H; Harbison MT; Davis DW; Nelkin G; Killion JJ; McConkey DJ; Dong Z; Fidler IJ
    Cancer Res; 2000 Jan; 60(1):2-7. PubMed ID: 10646841
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The novel highly lipophilic topoisomerase I inhibitor DB67 is effective in the treatment of liver metastases of murine CT-26 colon carcinoma.
    Lopez-Barcons LA; Zhang J; Siriwitayawan G; Burke TG; Perez-Soler R
    Neoplasia; 2004; 6(5):457-67. PubMed ID: 15548354
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Studies of the efficacy and pharmacology of irinotecan against human colon tumor xenograft models.
    Zamboni WC; Stewart CF; Cheshire PJ; Richmond LB; Hanna SK; Luo X; Poquette C; McGovren JP; Houghton JA; Houghton PJ
    Clin Cancer Res; 1998 Mar; 4(3):743-53. PubMed ID: 9533544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of poly(ADP-ribose) polymerase prevents irinotecan-induced intestinal damage and enhances irinotecan/temozolomide efficacy against colon carcinoma.
    Tentori L; Leonetti C; Scarsella M; Muzi A; Mazzon E; Vergati M; Forini O; Lapidus R; Xu W; Dorio AS; Zhang J; Cuzzocrea S; Graziani G
    FASEB J; 2006 Aug; 20(10):1709-11. PubMed ID: 16809434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detailed distribution of NK012, an SN-38-incorporating micelle, in the liver and its potent antitumor effects in mice bearing liver metastases.
    Takahashi A; Ohkohchi N; Yasunaga M; Kuroda J; Koga Y; Kenmotsu H; Kinoshita T; Matsumura Y
    Clin Cancer Res; 2010 Oct; 16(19):4822-31. PubMed ID: 20807756
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thrombospondin-1 plus irinotecan: a novel antiangiogenic-chemotherapeutic combination that inhibits the growth of advanced human colon tumor xenografts in mice.
    Allegrini G; Goulette FA; Darnowski JW; Calabresi P
    Cancer Chemother Pharmacol; 2004 Mar; 53(3):261-6. PubMed ID: 14658007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Irinophore C™, a lipid nanoparticulate formulation of irinotecan, improves vascular function, increases the delivery of sequentially administered 5-FU in HT-29 tumors, and controls tumor growth in patient derived xenografts of colon cancer.
    Neijzen R; Wong MQ; Gill N; Wang H; Karim T; Anantha M; Strutt D; Waterhouse D; Bally MB; Tai IT; Ng SS; Yapp DT
    J Control Release; 2015 Feb; 199():72-83. PubMed ID: 25497312
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin 15 offers selective protection from irinotecan-induced intestinal toxicity in a preclinical animal model.
    Cao S; Black JD; Troutt AB; Rustum YM
    Cancer Res; 1998 Aug; 58(15):3270-4. PubMed ID: 9699654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Irinotecan (CPT-11) and characteristic mucosal changes in the mouse ileum and cecum.
    Ikuno N; Soda H; Watanabe M; Oka M
    J Natl Cancer Inst; 1995 Dec; 87(24):1876-83. PubMed ID: 7494232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential regulation of type IV collagenases and metalloelastase in murine macrophages by the synthetic bacterial lipopeptide JBT 3002.
    Kumar R; Xie K; Eue I; Dong Z; Killion JJ; Fidler IJ
    Int J Immunopharmacol; 2000 Jun; 22(6):431-43. PubMed ID: 10727754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of irinotecan in combination with 5-fluorouracil or etoposide in xenograft models of colon adenocarcinoma and rhabdomyosarcoma.
    Houghton JA; Cheshire PJ; Hallman JD; Lutz L; Luo X; Li Y; Houghton PJ
    Clin Cancer Res; 1996 Jan; 2(1):107-18. PubMed ID: 9816097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced antitumor activity of 6-hydroxymethylacylfulvene in combination with irinotecan and 5-fluorouracil in the HT29 human colon tumor xenograft model.
    Britten CD; Hilsenbeck SG; Eckhardt SG; Marty J; Mangold G; MacDonald JR; Rowinsky EK; Von Hoff DD; Weitman S
    Cancer Res; 1999 Mar; 59(5):1049-53. PubMed ID: 10070962
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effect of chemotherapy using irinotecan (CPT-11) against recurrent colorectal cancer].
    Nishimura G; Satou T; Yoshimitsu Y; Kurosaka Y; Fujimura T; Sugiyama K; Kanno M; Yonemura Y; Miwa K; Miyazaki I
    Gan To Kagaku Ryoho; 1995 Jan; 22(1):93-7. PubMed ID: 7826085
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Irinotecan: various administration schedules, study of drug combinations, phase I experience].
    Boige V; Raymond E; Armand JP
    Bull Cancer; 1998 Dec; Spec No():26-32. PubMed ID: 9932081
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors.
    Houghton PJ; Cheshire PJ; Hallman JD; Lutz L; Friedman HS; Danks MK; Houghton JA
    Cancer Chemother Pharmacol; 1995; 36(5):393-403. PubMed ID: 7634381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differentiated human colorectal cancer cells protect tumor-initiating cells from irinotecan.
    Emmink BL; Van Houdt WJ; Vries RG; Hoogwater FJ; Govaert KM; Verheem A; Nijkamp MW; Steller EJ; Jimenez CR; Clevers H; Borel Rinkes IH; Kranenburg O
    Gastroenterology; 2011 Jul; 141(1):269-78. PubMed ID: 21459094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of oral irinotecan against neuroblastoma xenografts.
    Thompson J; Zamboni WC; Cheshire PJ; Richmond L; Luo X; Houghton JA; Stewart CF; Houghton PJ
    Anticancer Drugs; 1997 Apr; 8(4):313-22. PubMed ID: 9180383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.